ArticlePulmonary therapy2026
Oscillation and Lung Expansion Therapy as Rescue Airway Clearance in Critically Ill Adults: A Case Series.
Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRetained airway secretions and lobar collapse are common in hospitalized adults with advanced lung disease. Conventional airway clearance depends on respiratory effort, requiring both an adequate inspiratory volume and sufficient expiratory airflow, and on cough strength, and therefore fails most often in the patients who need it most. Oscillation and lung expansion (OLE) therapy delivers continuous positive expiratory pressure (CPEP), continuous high-frequency oscillation (CHFO), and aerosolized medication in a single 10-min treatment, but reported experience is largely confined to postoperative prophylaxis and the home setting.
methodsWe describe six consecutive adults (aged 18-77 years) treated with OLE (Volara system) at a Canadian tertiary center between March 2023 and April 2026, after conventional airway clearance had failed or after escalation to near-maximal noninvasive respiratory support. Feasibility (delivery of OLE as prescribed at the prevailing level of respiratory support) and tolerability (absence of adverse events or discontinuation for intolerance) were assessed retrospectively.
resultsDiagnoses were cystic fibrosis exacerbation (n = 2), thoracic malignancy with lobar collapse from mucus plugging (n = 2), metapneumovirus pneumonia in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome (n = 1), and autoimmune pulmonary alveolar proteinosis with sepsis (n = 1). In each, the realistic alternatives were bronchoscopy, intubation, or palliation. All six demonstrated secretion clearance, radiographic re-expansion, or both. Supplemental oxygen requirements fell in five, two did not require the intensive care transfer or intubation that had been anticipated, and no adverse event was observed following OLE, including in one patient with a recently drained pneumothorax. One patient with metastatic malignancy died of her cancer during the same admission despite radiographic re-expansion.
conclusionsOLE was feasible and well tolerated when used as rescue airway clearance in high-acuity adults. These observations, while hypothesis-generating, require prospective, protocolized evaluation before OLE can be recommended for this indication.
Indexed as
Identifiers
42834317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.